Literature DB >> 33737109

How Far Have We Explored Fungi to Fight Cancer?

Chee Wun How1, Yong Sze Ong1, Sze Shin Low2, Ashok Pandey3, Pau Loke Show4, Jhi Biau Foo5.   

Abstract

The use of fungal cultures have been well documented in human history. Although its used in healthcare, like penicillin and statins, have saved countless of lives, but there is still no fungal products that are specifically indicated for cancers. Research into fungal-derived materials to curb cancers in the recent decades have made a considerable progress in terms of drug delivery vehicles, anticancer active ingredients and cancer immunotherapy. Various parts of the organisms have successfully been exploited to achieve specific tasks. Apart from the identification of novel anticancer compound from fungi, its native capsular structure can also be used as drug cargo to achieve higher oral bioavailability. This review summarizes the anticancer potential of fungal-derived materials, highlighting the role of capsular polysaccharides, proteins, and other structures in variety of innovative utilities to fit the current pharmaceutical technology. Many bioactive compounds isolated from fungi have also been formulated into nanoparticles to achieve greater anticancer activity. The progress of fungal compounds and their analogues in clinical trials is also highlighted. In addition, the potential of various fungal species to be developed for anticancer immunotherapy are also discussed.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Clinical Trials; Drug Delivery; Formulation; Fungi; Vaccine

Year:  2021        PMID: 33737109     DOI: 10.1016/j.semcancer.2021.03.009

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  40 in total

1.  Yin Yang 1-induced activation of LINC01133 facilitates the progression of pancreatic cancer by sponging miR-199b-5p to upregulate myelin regulatory factor expression.

Authors:  Xi Yang; Leiming Wang; Fei Zhou; Song Ye; Qianghu Sun
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

2.  MiR-19a suppresses ferroptosis of colorectal cancer cells by targeting IREB2.

Authors:  Hongwei Fan; Rong Ai; Suen Mu; Xuemin Niu; Zhengrong Guo; Lin Liu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Long non-coding RNA TRPM2 antisense RNA as a potential therapeutic target promotes tumorigenesis and metastasis in esophageal cancer.

Authors:  Wei Wang; Yukai Dai; Xin Yang; Xinming Xiong
Journal:  Bioengineered       Date:  2022-02       Impact factor: 6.832

4.  Overexpression of microRNA-145 enhanced docetaxel sensitivity in breast cancer cells via inactivation of protein kinase B gamma-mediated phosphoinositide 3-kinase -protein kinase B pathway.

Authors:  Ying Zhou; Wei Cai; Hailin Lu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

5.  The role of gut microbiota in patients with benign and malignant brain tumors: a pilot study.

Authors:  Haixiao Jiang; Wei Zeng; Xiaoli Zhang; Yunlong Pei; Hengzhu Zhang; Yuping Li
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

6.  Potential antitumor and anti-inflammatory activities of an extracellular polymeric substance (EPS) from Bacillus subtilis isolated from a housefly.

Authors:  Lingxiu Zhang; Huilan Yi
Journal:  Sci Rep       Date:  2022-01-26       Impact factor: 4.379

7.  Inhibin subunit beta A promotes cell proliferation and metastasis of breast cancer through Wnt/β-catenin signaling pathway.

Authors:  Tao Xueqin; Mei Jinhong; Huang Yuping
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 8.  A Comprehensive Insight into Fungal Enzymes: Structure, Classification, and Their Role in Mankind's Challenges.

Authors:  Hamada El-Gendi; Ahmed K Saleh; Raied Badierah; Elrashdy M Redwan; Yousra A El-Maradny; Esmail M El-Fakharany
Journal:  J Fungi (Basel)       Date:  2021-12-28

9.  Identification and validation of an autophagy-related signature for predicting survival in lower-grade glioma.

Authors:  Shaobin Feng; Huiling Liu; Xushuai Dong; Peng Du; Hua Guo; Qi Pang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

10.  Utilizing network pharmacology to explore potential mechanisms of YiSui NongJian formula in treating myelodysplastic syndrome.

Authors:  Lerong Qin; Haiyan Chen; Xiaoqing Ding; Ming Guo; Haiyan Lang; Junxia Liu; Ling Li; Jing Liao; Junyao Liao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.